-
Product Insights
Nasopharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Nasopharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Nasopharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Keratoconjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-500 in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAK-500 in Malignant Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAK-500 in Malignant Mesothelioma Drug Details: TAK-500 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KVA-12123 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KVA-12123 in Ovarian Cancer Drug Details: KVA-12123 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) Drug Details: NKTR-255 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Porustobart in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Porustobart in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Porustobart in Melanoma Drug Details: HBM-4003 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Porustobart in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Porustobart in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Porustobart in Non-Small Cell Lung Cancer Drug Details: HBM-4003 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NN-1845 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NN-1845 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HRAIN-002 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HRAIN-002 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HRAIN-002 in Refractory Multiple Myeloma Drug Details:HRAIN-002 is under development for the...